+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2019

  • ID: 4861736
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 60 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Acucela Inc
  • Aerie Pharmaceuticals Inc
  • Cell Medica Ltd
  • Generium
  • NeuBase Therapeutics Inc
  • Oxurion NV
  • MORE
Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2019

Summary

The Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2019, provides an overview of the Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline landscape.

Proliferative diabetic retinopathy (PDR) is the most severe type of diabetic retinopathy. Proliferative diabetic retinopathy occurs where fragile new blood vessels form on the surface of the retina over time. These abnormal vessels can bleed or develop scar tissue causing severe loss of sight. Predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy and tobacco use. Symptoms include spots or dark strings floating in vision, vision loss, fluctuating vision, blurred vision and difficulty with color perception.

Report Highlights

The Publisher's Pharmaceutical and Healthcare latest pipeline guide Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Proliferative Diabetic Retinopathy (PDR) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 2 and 3 respectively.

Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Acucela Inc
  • Aerie Pharmaceuticals Inc
  • Cell Medica Ltd
  • Generium
  • NeuBase Therapeutics Inc
  • Oxurion NV
  • MORE
Introduction
Report Coverage
Proliferative Diabetic Retinopathy (PDR) - Overview
Proliferative Diabetic Retinopathy (PDR) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Proliferative Diabetic Retinopathy (PDR) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Proliferative Diabetic Retinopathy (PDR) - Companies Involved in Therapeutics Development
Acucela Inc
Aerie Pharmaceuticals Inc
Antisense Therapeutics Ltd
Cell Medica Ltd
Generium
NeuBase Therapeutics Inc
Oxurion NV
Protheragen Inc
Proliferative Diabetic Retinopathy (PDR) - Drug Profiles
AR-13503 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
atesidorsen sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brolucizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emixustat hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit SCG3 for Metabolic Disorders, Oncology and Ophthalmology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ranibizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
squalamine lactate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
THR-687 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proliferative Diabetic Retinopathy (PDR) - Dormant Projects
Proliferative Diabetic Retinopathy (PDR) - Product Development Milestones
Featured News & Press Releases
May 08, 2016: Acucela Initiates Phase 2 Clinical Trial Addressing Proliferative Diabetic Retinopathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Proliferative Diabetic Retinopathy (PDR), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Proliferative Diabetic Retinopathy (PDR) - Pipeline by Acucela Inc, H2 2019
Proliferative Diabetic Retinopathy (PDR) - Pipeline by Aerie Pharmaceuticals Inc, H2 2019
Proliferative Diabetic Retinopathy (PDR) - Pipeline by Antisense Therapeutics Ltd, H2 2019
Proliferative Diabetic Retinopathy (PDR) - Pipeline by Cell Medica Ltd, H2 2019
Proliferative Diabetic Retinopathy (PDR) - Pipeline by Generium, H2 2019
Proliferative Diabetic Retinopathy (PDR) - Pipeline by NeuBase Therapeutics Inc, H2 2019
Proliferative Diabetic Retinopathy (PDR) - Pipeline by Oxurion NV, H2 2019
Proliferative Diabetic Retinopathy (PDR) - Pipeline by Protheragen Inc, H2 2019
Proliferative Diabetic Retinopathy (PDR) - Dormant Projects, H2 2019

List of Figures
Number of Products under Development for Proliferative Diabetic Retinopathy (PDR), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Acucela Inc
  • Aerie Pharmaceuticals Inc
  • Antisense Therapeutics Ltd
  • Cell Medica Ltd
  • Generium
  • NeuBase Therapeutics Inc
  • Oxurion NV
  • Protheragen Inc
Note: Product cover images may vary from those shown
Adroll
adroll